UCB - Daily - Technical analysis published on 03/13/2024 (GMT)
- 140
- 0
Click here for a new analysis!
- Timeframe : Daily
- - Analysis generated on
- Status : TARGET REACHED
Summary of the analysis
Additional analysis
Quotes
The UCB price is 108.00 EUR. On the day, this instrument lost -0.14% with the lowest point at 107.70 EUR and the highest point at 108.60 EUR. The deviation from the price is +0.28% for the low point and -0.55% for the high point.A bullish opening was detected by the Central Gaps scanner. Buyers are trying to impose a bullish momentum in the very short term.
Bullish opening
Type : Bullish
Timeframe : Openning
Here is a more detailed summary of the historical variations registered by UCB:
Near a new HIGH record (5 years)
Type : Bullish
Timeframe : Weekly
Near a new HIGH record (1 year)
Type : Bullish
Timeframe : Weekly
Near a new HIGH record (1st january)
Type : Bullish
Timeframe : Weekly
Near a new HIGH record (1 month)
Type : Bullish
Timeframe : Weekly
Technical
Technical analysis of UCB in Daily shows a strongly overall bullish trend. 92.86% of the signals given by moving averages are bullish. The overall trend is supported by the strong bullish signals from short-term moving averages. There is no crossing of moving average by the price or crossing of moving averages between themselves.
In fact, according to the parameters integrated into the Central Analyzer system, 12 technical indicators out of 18 analysed are currently bullish. Caution: the Central Indicators scanner currently detects an excess:
RSI indicator is overbought : over 70
Type : Neutral
Timeframe : Daily
Williams %R indicator is overbought : over -20
Type : Neutral
Timeframe : Daily
Price is back under the pivot point
Type : Bearish
Timeframe : Weekly
Central Patterns, the market scanner focusing on chart patterns, resistances and supports found this result:
Near resistance of channel
Type : Bearish
Timeframe : Daily
No result was found by the Central Candlesticks scanner on Japanese candlesticks.
S3 | S2 | S1 | Price | R1 | R2 | |
---|---|---|---|---|---|---|
ProTrendLines | 87.30 | 97.11 | 104.45 | 108.00 | 108.39 | 112.77 |
Change (%) | -19.17% | -10.08% | -3.29% | - | +0.36% | +4.42% |
Change | -20.70 | -10.89 | -3.55 | - | +0.39 | +4.77 |
Level | Intermediate | Intermediate | Minor | - | Intermediate | Major |
To determine price objectives, it is also possible to use the pivot points. Here is the price position in relation to pivot points:
Pivot points | S3 | S2 | S1 | PP | R1 | R2 | R3 |
---|---|---|---|---|---|---|---|
Standard | 104.65 | 105.65 | 106.90 | 107.90 | 109.15 | 110.15 | 111.40 |
Camarilla | 107.53 | 107.74 | 107.94 | 108.15 | 108.36 | 108.56 | 108.77 |
Woodie | 104.78 | 105.71 | 107.03 | 107.96 | 109.28 | 110.21 | 111.53 |
Fibonacci | 105.65 | 106.51 | 107.04 | 107.90 | 108.76 | 109.29 | 110.15 |
Pivot points | S3 | S2 | S1 | PP | R1 | R2 | R3 |
---|---|---|---|---|---|---|---|
Standard | 103.47 | 104.83 | 107.37 | 108.73 | 111.27 | 112.63 | 115.17 |
Camarilla | 108.83 | 109.19 | 109.54 | 109.90 | 110.26 | 110.62 | 110.97 |
Woodie | 104.05 | 105.13 | 107.95 | 109.03 | 111.85 | 112.93 | 115.75 |
Fibonacci | 104.83 | 106.32 | 107.24 | 108.73 | 110.22 | 111.14 | 112.63 |
Pivot points | S3 | S2 | S1 | PP | R1 | R2 | R3 |
---|---|---|---|---|---|---|---|
Standard | 71.33 | 78.55 | 92.52 | 99.74 | 113.71 | 120.93 | 134.90 |
Camarilla | 100.67 | 102.62 | 104.56 | 106.50 | 108.44 | 110.39 | 112.33 |
Woodie | 74.72 | 80.24 | 95.91 | 101.43 | 117.10 | 122.62 | 138.29 |
Fibonacci | 78.55 | 86.64 | 91.64 | 99.74 | 107.83 | 112.83 | 120.93 |
Numerical data
The following is the status of the technical indicators and moving averages at the time of publication of this technical analysis:
RSI (14): | 74.91 | |
MACD (12,26,9): | 5.1900 | |
Directional Movement: | 25.18 | |
AROON (14): | 85.71 | |
DEMA (21): | 109.96 | |
Parabolic SAR (0,02-0,02-0,2): | 101.39 | |
Elder Ray (13): | 2.38 | |
Super Trend (3,10): | 102.80 | |
Zig ZAG (10): | 108.05 | |
VORTEX (21): | 1.3300 | |
Stochastique (14,3,5): | 88.10 | |
TEMA (21): | 111.19 | |
Williams %R (14): | -13.63 | |
Chande Momentum Oscillator (20): | 11.46 | |
Repulse (5,40,3): | 0.8100 | |
ROCnROLL: | 1 | |
TRIX (15,9): | 0.8000 | |
Courbe Coppock: | 27.80 |
MA7: | 108.61 | |
MA20: | 102.40 | |
MA50: | 92.56 | |
MA100: | 82.19 | |
MAexp7: | 107.91 | |
MAexp20: | 103.08 | |
MAexp50: | 94.59 | |
MAexp100: | 88.05 | |
Price / MA7: | -0.56% | |
Price / MA20: | +5.47% | |
Price / MA50: | +16.68% | |
Price / MA100: | +31.40% | |
Price / MAexp7: | +0.08% | |
Price / MAexp20: | +4.77% | |
Price / MAexp50: | +14.18% | |
Price / MAexp100: | +22.66% |
News
Don't forget to follow the news on UCB. At the time of publication of this analysis, the latest news was as follows:
- First Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis
- BIMZELX® 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count
- UCB on Growth Path for a Decade Plus
- ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positive
- UCB presents new data about the real-world experience of FINTEPLA® (fenfluramine) and rare epilepsy syndromes at 2023 American Epilepsy Society (AES) Annual Meeting
Add a comment
Comments
0 comments on the analysis UCB - Daily